Thursday December 11, 7:01 am Eastern Time
Company Press Release
Leading Ophthalmic Surgeons Join Sunrise Scientific Advisory Board
FREMONT, Calif.--(BW HealthWire)--Dec. 11, 1997--Today Sunrise Technologies International Inc. (OTC:SNRS - news) announced the formation of a Scientific Advisory Board comprised of leading ophthalmic surgeons from around the world.
C. Russell Trenary III, president and CEO stated that, ''We are extremely proud to be associated with these surgeons who are recognized as some of the best ophthalmologists in the world.''
Trenary continued, ''My management team is unconditionally committed to building an organization that listens and acts on advice from customers. The purpose of the Scientific Advisory Board is to help ensure that we receive the best information available from the global ophthalmic community. For that to happen you need great doctors to be part of the process, and we believe this group represents some of the leading ophthalmic minds available.''
Members of the company's Scientific Advisory Board are:
Alan B. Aker, M.D., Aker-Kasten Cataract and Laser Institute, Boca Raton, FL;
Sandra C. Belmont, M.D., Associate Professor at Cornell Medical College -- New York Hospital, Director of the Laser Vision Correction Center, New York, NY;
David C. Brown, M.D., Associate Clinical Professor at University of South Florida, Eye Centers of Florida, Fort Myers, FL;
Paul H. Ernest, M.D., Associate Clinical Professor at Kresge Eye Institute at Wayne State University; Eye Care Physicians of
Michigan, Jackson, MI;
Donald G. Johnson, M.D., Medical Surgical Director, London Place Eye Center, New Westminster, Canada;
Thomas Kohnen, M.D., Johann Wolfgang Goethe -- University, Frankfurt, Germany;
Douglas D. Koch, M.D., Associate Professor of Ophthalmology at Baylor College of Medicine; Cullen Eye Institute, Houston,TX;
Robert Gale Martin, M.D., Carolina Eye Associates, Southern Pines, NC;
Peter J. McDonnell, M.D., Professor of Ophthalmology at the University of Southern California; Doheny Eye Institute, Los Angeles, CA;
Hugo Nano, M.D., Clinica de Ojos, Buenos Aires, Argentina;
Emanuel S. Rosen, M.D., Consultant Ophthalmic Surgeon, Manchester, U.K., and Manor Lodge, (Alexandra Hospital), Cheadle, U.K.;
Donald R. Sanders, M.D., Ph.D., Center for Clinical Research, Elmhurst, IL; and
Rogelio Villareal, M.D., Centro de Cornea, Monterrey, Mexico.
Dr. David C. Brown of Eye Centers of Florida explained, ''This is an exciting time to be associated with Sunrise Technologies. The Scientific Advisory Board will be a valuable resource to both the operation of the company and the future development of its products. This Board will also assist Sunrise Technologies in being receptive to the needs and suggestions of its customer base.''
Founded in 1987 the company produces and markets high technology products revolutionizing treatment methods in eye care. The company develops holmium laser-based systems which utilize a patented process for shrinking collagen developed by Dr. Bruce Sand (the ''Sand Process'') in correcting ophthalmic conditions.
Its CorneaSparing LTK(TM) System(1) is a non-contact simultaneous application for correction of hyperopia (farsightedness), presbyopia (loss of focus due to natural aging), and overcorrection resulting from PRK and LASIK treatments for myopia. The system is currently in use in Europe and the Americas, and is in FDA clinical trials in the United States.
Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties which may cause actual results to differ materially from the statements made, including market potential, regulatory clearances, business growth, and other risks listed from time to time in the company's Securities and Exchange Commission (SEC) filings. These forward-looking statements represent the company's judgment, as of the date of this release, and the company disclaims any intent or obligation to update these forward-looking statements.
Internet users can access Sunrise's World Wide Web site at sunrise-tech.com .
(1) Caution -- Investigational Device: Federal law restricts this device to investigational use in the U.S.
Contact:
Sunrise Technologies
Susan Lorigan, Investor Relations |
